---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-115211"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:39:04.091185+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma FY2025 net loss $41.9M; setrusumab Phase 3 studies miss primary endpoints, show BMD gains

## Summary
- Cash $41.0M as of Dec 31, 2025; expected runway into mid-2027 (from $69.8M end 2024).
- Setrusumab Phase 3 Orbit & Cosmic missed primary endpoint (annualized clinical fracture rate) but achieved high statistical significance on BMD improvement.
- Setrusumab showed vertebral fracture reductions and statistically significant PRO improvements in pain/daily activity in pediatric patients.
- Alvelestat site feasibility for Phase 3 in AATD-LD complete; partnering discussions ongoing; Phase 2b in bronchiectasis designed.
- Vantictumab outlicensed to āshibio; Phase 2 in osteopetrosis planned H2 2026.

## SEC filing metadata
- accession: 0001193125-26-115211
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312526115211/0001193125-26-115211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312526115211/mreo-20260319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-115211
- JSON: https://secwatch.observer/filing/0001193125-26-115211.json
- Plain text: https://secwatch.observer/filing/0001193125-26-115211.txt

## Key facts
- Earnings Releases
  Mereo BioPharma Group plc reported financial results for the full year ended December 31, 2025.
  - Period: the full year ended December 31, 2025
  - Result: reported results
  source text: Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the full year ended December 31, 2025, and provided an update on recent corporate developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526115211/0001193125-26-115211-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.